Programmed Cell Death Ligand as a Biomarker for Response to Immunotherapy: Contribution of Mass Spectrometry-Based Analysis

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 1001 - 1001

Published: March 17, 2025

Immune checkpoint inhibition is a major component in today’s cancer immunotherapy. In recent years, the FDA has approved number of immune inhibitors (ICIs) for treatment melanoma, non-small-cell lung, breast and gastrointestinal cancers. These inhibitors, which target cytotoxic T-lymphocyte antigen-4, programmed cell death (PD-1), ligand (PD-L1) checkpoints have assumed leading role The same exert significant antitumor effects by overcoming tumor evasion reversing T-cell exhaustion. initial impact this therapy was justly described as revolutionary, however, clinical well research data followed demonstrated that these innovative drugs are costly, associated with potentially severe adverse effects, only benefit small subset patients. limitations encouraged enhanced efforts to identify predictive biomarkers stratify patients who most likely from form therapy. discovery characterization class pivotal guiding individualized against various forms cancer. Currently, there three FDA-approved biomarkers, none on its own can deliver reliable precise response Present literature identifies absence poor understanding mechanisms behind resistance main obstacles facing ICIs present text, we discuss dual PD-L1 biomarker immunotherapy an checkpoint. contribution mass spectrometry-based analysis, particularly protein post-translational modifications performance underlined.

Language: Английский

Uncovering global research frontiers in deubiquitinating enzymes and immunotherapy: A bibliometric study

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: March 25, 2025

Recently, immunotherapy has been a key therapeutic strategy for cancer. Deubiquitinating enzymes (DUBs), which are protein-modifying enzymes, have crucial role in the pathogenesis of cancer, autoimmune diseases, and inflammation. DUBs influence tumor immune microenvironment by regulating cell functions signaling pathways. Thus, potential applications piqued interest scientific community. This study performed bibliometric analysis to comprehensively examine research hotspots trends this field, providing theoretical foundations guidance future research. Studies associated with conducted over decade (2014 2024) were searched extracted from Web Science Collection database. The was using CiteSpace, VOSviewer, Bibliometrix package R software. Visualizations generated countries, institutions, authors, journals, references, keyword co-occurrences. In total, 321 articles related retrieved. number publications increased markedly since 2020. China had highest publications, while United States exerted most field. Zhang Jinfang influential author Zhejiang University institution publications. Nature cited journal (807 total citations). Keyword revealed that primary expression, immunotherapy, ubiquitination, degradation, emerging frontiers offering novel strategies application immunotherapy.

Language: Английский

HRD1 regulates tumor-associated macrophage polarization through USP7 and promotes lung cancer development

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 159, P. 114944 - 114944

Published: May 24, 2025

Language: Английский